In most hospitals worldwide, the clinical management of BC is mainly based on clinical-pathological features and the assessment of few surrogate biomarkers, namely, the estrogen receptor (ER), the progesterone receptor (PR), the human epidermal growth factor receptor-2 (ERBB2), and Ki67. This evidence concerns the gene ESR1 and breast cancer.